It's been a pretty great week for SBC Medical Group Holdings Incorporated (NASDAQ:SBC) shareholders, with its shares surging 20% to US$3.66 in the week since its latest second-quarter results. Statutory earnings per share of US$0.10 unfortunately missed expectations by 11%, although it was encouraging to see revenues of US$49m exceed expectations by 8.2%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Taking into account the latest results, the current consensus from SBC Medical Group Holdings' four analysts is for revenues of US$186.5m in 2026. This would reflect a satisfactory 6.5% increase on its revenue over the past 12 months. Statutory earnings per share are expected to dip 4.5% to US$0.46 in the same period. In the lead-up to this report, the analysts had been modelling revenues of US$181.0m and earnings per share (EPS) of US$0.45 in 2026. There doesn't appear to have been a major change in sentiment following the results, other than the slight bump in revenue estimates.

Even though revenue forecasts increased, there was no change to the consensus price target of US$8.50, suggesting the analysts are focused on earnings as the driver of value creation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values SBC Medical Group Holdings at US$10.00 per share, while the most bearish prices it at US$7.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that SBC Medical Group Holdings is forecast to grow faster in the future than it has in the past, with revenues expected to display 13% annualised growth until the end of 2026. If achieved, this would be a much better result than the 6.9% annual decline over the past year. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 4.9% annually. Not only are SBC Medical Group Holdings' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple SBC Medical Group Holdings analysts - going out to 2028, and you can see them free on our platform here.

We also provide an overview of the SBC Medical Group Holdings Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.